NCT02254278 · BASELINE

Baseline characteristics

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer · Source last updated 2026-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
157
group Id
BG001
value
149
group Id
BG002
value
306
units
Participants

groups

description
Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks IMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
id
BG000
title
IMRT 6 Weeks + Cisplatin
description
IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
id
BG001
title
IMRT 5 Weeks
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
28
group Id
BG001
value
14
group Id
BG002
value
42
title
≤ 49
measurements
group Id
BG000
value
56
group Id
BG001
value
60
group Id
BG002
value
116
title
50 - 59
measurements
group Id
BG000
value
46
group Id
BG001
value
55
group Id
BG002
value
101
title
60 - 69
measurements
group Id
BG000
value
27
group Id
BG001
value
20
group Id
BG002
value
47
title
≥ 70
param Type
COUNT_OF_PARTICIPANTS
title
Age, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
24
group Id
BG001
value
25
group Id
BG002
value
49
title
Female
measurements
group Id
BG000
value
133
group Id
BG001
value
124
group Id
BG002
value
257
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
7
group Id
BG002
value
10
title
Hispanic or Latino
measurements
group Id
BG000
value
143
group Id
BG001
value
130
group Id
BG002
value
273
title
Not Hispanic or Latino
measurements
group Id
BG000
value
11
group Id
BG001
value
12
group Id
BG002
value
23
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
American Indian or Alaska Native
measurements
group Id
BG000
value
0
group Id
BG001
value
4
group Id
BG002
value
4
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
Black or African American
measurements
group Id
BG000
value
151
group Id
BG001
value
130
group Id
BG002
value
281
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
4
group Id
BG001
value
12
group Id
BG002
value
16
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
132
group Id
BG001
value
113
group Id
BG002
value
245
title
0: Asymptomatic
measurements
group Id
BG000
value
25
group Id
BG001
value
36
group Id
BG002
value
61
title
1: Symptomatic but completely ambulatory
param Type
COUNT_OF_PARTICIPANTS
title
Zubrod performance status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
112
group Id
BG001
value
101
group Id
BG002
value
213
title
0
measurements
group Id
BG000
value
26
group Id
BG001
value
32
group Id
BG002
value
58
title
>0 - <5
measurements
group Id
BG000
value
19
group Id
BG001
value
16
group Id
BG002
value
35
title
5 - 10
description
Smoking history as measured in pack-years, calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked.
param Type
COUNT_OF_PARTICIPANTS
title
Smoking history (pack years)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
13
group Id
BG002
value
17
title
Oropharynx NOS (not otherwise specified)
measurements
group Id
BG000
value
83
group Id
BG001
value
78
group Id
BG002
value
161
title
Tonsillar fossa, tonsil
measurements
group Id
BG000
value
68
group Id
BG001
value
58
group Id
BG002
value
126
title
Base of tongue
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Pharyngeal oropharynx
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Posterior pharyngeal wall
param Type
COUNT_OF_PARTICIPANTS
title
Primary tumor site
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
64
group Id
BG001
value
51
group Id
BG002
value
115
title
T1
measurements
group Id
BG000
value
67
group Id
BG001
value
80
group Id
BG002
value
147
title
T2
measurements
group Id
BG000
value
26
group Id
BG001
value
18
group Id
BG002
value
44
title
T3
description
Tumor stage per the American Joint Committee on Cancer (AJCC) 7th ed. refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b.
param Type
COUNT_OF_PARTICIPANTS
title
T stage, clinical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
7
group Id
BG002
value
13
title
N0
measurements
group Id
BG000
value
28
group Id
BG001
value
34
group Id
BG002
value
62
title
N1
measurements
group Id
BG000
value
24
group Id
BG001
value
19
group Id
BG002
value
43
title
N2a
measurements
group Id
BG000
value
99
group Id
BG001
value
89
group Id
BG002
value
188
title
N2b
description
Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes.
param Type
COUNT_OF_PARTICIPANTS
title
N stage, clinical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
52
group Id
BG001
value
47
group Id
BG002
value
99
title
Unilateral
measurements
group Id
BG000
value
105
group Id
BG001
value
102
group Id
BG002
value
207
title
Bilateral
description
Radiation therapy plan included unilateral or bilateral radiation to the neck, as provided by the treating site at stratification.
param Type
COUNT_OF_PARTICIPANTS
title
Radiation Therapy (RT) planning (as stratified)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
16
group Id
BG001
value
21
group Id
BG002
value
37
title
Unilateral
measurements
group Id
BG000
value
136
group Id
BG001
value
125
group Id
BG002
value
261
title
Bilateral
measurements
group Id
BG000
value
5
group Id
BG001
value
3
group Id
BG002
value
8
title
Unknown
description
Radiation therapy plan included unilateral or bilateral radiation to the neck, as provided by central review by the study radiation oncologist.
param Type
COUNT_OF_PARTICIPANTS
title
RT planning (per central review)
unit Of Measure
Participants

population Description

Randomized and eligible patients

Complete source fields

denoms

counts
group Id
BG000
value
157
group Id
BG001
value
149
group Id
BG002
value
306
units
Participants

groups

description
Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks IMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
id
BG000
title
IMRT 6 Weeks + Cisplatin
description
IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
id
BG001
title
IMRT 5 Weeks
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
28
group Id
BG001
value
14
group Id
BG002
value
42
title
≤ 49
measurements
group Id
BG000
value
56
group Id
BG001
value
60
group Id
BG002
value
116
title
50 - 59
measurements
group Id
BG000
value
46
group Id
BG001
value
55
group Id
BG002
value
101
title
60 - 69
measurements
group Id
BG000
value
27
group Id
BG001
value
20
group Id
BG002
value
47
title
≥ 70
param Type
COUNT_OF_PARTICIPANTS
title
Age, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
24
group Id
BG001
value
25
group Id
BG002
value
49
title
Female
measurements
group Id
BG000
value
133
group Id
BG001
value
124
group Id
BG002
value
257
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
7
group Id
BG002
value
10
title
Hispanic or Latino
measurements
group Id
BG000
value
143
group Id
BG001
value
130
group Id
BG002
value
273
title
Not Hispanic or Latino
measurements
group Id
BG000
value
11
group Id
BG001
value
12
group Id
BG002
value
23
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
American Indian or Alaska Native
measurements
group Id
BG000
value
0
group Id
BG001
value
4
group Id
BG002
value
4
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
Black or African American
measurements
group Id
BG000
value
151
group Id
BG001
value
130
group Id
BG002
value
281
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
4
group Id
BG001
value
12
group Id
BG002
value
16
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
132
group Id
BG001
value
113
group Id
BG002
value
245
title
0: Asymptomatic
measurements
group Id
BG000
value
25
group Id
BG001
value
36
group Id
BG002
value
61
title
1: Symptomatic but completely ambulatory
param Type
COUNT_OF_PARTICIPANTS
title
Zubrod performance status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
112
group Id
BG001
value
101
group Id
BG002
value
213
title
0
measurements
group Id
BG000
value
26
group Id
BG001
value
32
group Id
BG002
value
58
title
>0 - <5
measurements
group Id
BG000
value
19
group Id
BG001
value
16
group Id
BG002
value
35
title
5 - 10
description
Smoking history as measured in pack-years, calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked.
param Type
COUNT_OF_PARTICIPANTS
title
Smoking history (pack years)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
13
group Id
BG002
value
17
title
Oropharynx NOS (not otherwise specified)
measurements
group Id
BG000
value
83
group Id
BG001
value
78
group Id
BG002
value
161
title
Tonsillar fossa, tonsil
measurements
group Id
BG000
value
68
group Id
BG001
value
58
group Id
BG002
value
126
title
Base of tongue
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Pharyngeal oropharynx
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
Posterior pharyngeal wall
param Type
COUNT_OF_PARTICIPANTS
title
Primary tumor site
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
64
group Id
BG001
value
51
group Id
BG002
value
115
title
T1
measurements
group Id
BG000
value
67
group Id
BG001
value
80
group Id
BG002
value
147
title
T2
measurements
group Id
BG000
value
26
group Id
BG001
value
18
group Id
BG002
value
44
title
T3
description
Tumor stage per the American Joint Committee on Cancer (AJCC) 7th ed. refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b.
param Type
COUNT_OF_PARTICIPANTS
title
T stage, clinical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
6
group Id
BG001
value
7
group Id
BG002
value
13
title
N0
measurements
group Id
BG000
value
28
group Id
BG001
value
34
group Id
BG002
value
62
title
N1
measurements
group Id
BG000
value
24
group Id
BG001
value
19
group Id
BG002
value
43
title
N2a
measurements
group Id
BG000
value
99
group Id
BG001
value
89
group Id
BG002
value
188
title
N2b
description
Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes.
param Type
COUNT_OF_PARTICIPANTS
title
N stage, clinical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
52
group Id
BG001
value
47
group Id
BG002
value
99
title
Unilateral
measurements
group Id
BG000
value
105
group Id
BG001
value
102
group Id
BG002
value
207
title
Bilateral
description
Radiation therapy plan included unilateral or bilateral radiation to the neck, as provided by the treating site at stratification.
param Type
COUNT_OF_PARTICIPANTS
title
Radiation Therapy (RT) planning (as stratified)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
16
group Id
BG001
value
21
group Id
BG002
value
37
title
Unilateral
measurements
group Id
BG000
value
136
group Id
BG001
value
125
group Id
BG002
value
261
title
Bilateral
measurements
group Id
BG000
value
5
group Id
BG001
value
3
group Id
BG002
value
8
title
Unknown
description
Radiation therapy plan included unilateral or bilateral radiation to the neck, as provided by central review by the study radiation oncologist.
param Type
COUNT_OF_PARTICIPANTS
title
RT planning (per central review)
unit Of Measure
Participants

population Description

Randomized and eligible patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice